D-JNKI-1 - 99%, high purity , CAS No.1445179-97-4

Item Number

D646251

• Synonyms: brimapitide|1445179-97-4|XG-102|UNII-2K30142185|2K30142185|D-Asp-D-gln-D-ser-D-arg-D-pro-D-val-D-gln-D-pro-D-phe-D-leu-D-asn-D-leu-D-thr-D-thr-D-pro-D-arg-D-lys-D-pro-D-arg-D-pro-D-pro-D-arg-D-arg-D-arg-D-gln-D-arg-D-arg-D-lys-D-lys-D-arg-gly-NH2|BRIMAPIT
• Specifications & Purity: 99%
• Storage Temp: Desiccated,Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK .

In Vitro

D-JNKI-1 (AM-111; 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

D-JNKI-1 (AM-111; 10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner . D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4 + and CD8 + cells in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:JNK